UCLA scientists discovered that squamous cell skin cancer resists treatment by adapting its metabolism, switching from ...

Patients with pulmonary arterial hypertension who received bilateral lung or heart-lung transplants showed similar survival ...

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

Mosliciguat, an inhaled once-daily PH medication, can reduce the resistance against blood flow in lung blood vessels, a Phase ...

At ERS 2024, experts debated systemic thrombolysis vs mechanical and surgical treatments for high-risk pulmonary embolism, ...

BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension registry (CTEPH), conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term ...

Using advanced computer methods, experts identified the genes that make cholera bacteria dangerous. This breakthrough could ...

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 ...

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...